Zacks Research Has Weak Outlook for Henry Schein Q1 Earnings

Henry Schein, Inc. (NASDAQ:HSIC) – Investment analysts at Zacks Research cut their Q1 2025 EPS estimates for shares of Henry Schein in a report issued on Tuesday, March 18th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $1.11 per share for the quarter, down from their previous estimate of $1.17. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. Zacks Research also issued estimates for Henry Schein’s Q2 2025 earnings at $1.21 EPS, Q3 2025 earnings at $1.26 EPS, Q4 2025 earnings at $1.26 EPS, FY2025 earnings at $4.84 EPS, Q1 2026 earnings at $1.32 EPS, Q2 2026 earnings at $1.36 EPS, Q3 2026 earnings at $1.25 EPS, Q4 2026 earnings at $1.39 EPS, FY2026 earnings at $5.31 EPS and FY2027 earnings at $5.74 EPS.

HSIC has been the subject of a number of other research reports. Bank of America upgraded Henry Schein from an “underperform” rating to a “buy” rating and boosted their price objective for the stock from $69.00 to $84.00 in a report on Monday, January 6th. Mizuho assumed coverage on Henry Schein in a report on Wednesday, December 4th. They issued a “neutral” rating and a $75.00 target price on the stock. Jefferies Financial Group raised their price target on shares of Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. Barrington Research reiterated an “outperform” rating and issued a $90.00 price target on shares of Henry Schein in a research note on Wednesday, February 26th. Finally, Wells Fargo & Company assumed coverage on shares of Henry Schein in a research report on Friday, February 14th. They issued an “equal weight” rating and a $80.00 price target for the company. Six investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $81.10.

Henry Schein Trading Down 0.6 %

Henry Schein stock opened at $70.45 on Thursday. Henry Schein has a 52 week low of $63.67 and a 52 week high of $82.49. The stock has a market capitalization of $8.75 billion, a P/E ratio of 28.99, a PEG ratio of 2.13 and a beta of 0.90. The stock has a 50-day simple moving average of $74.83 and a 200 day simple moving average of $72.61. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.23 by ($0.04). The business had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.66 earnings per share.

Insider Activity

In other news, CEO Bradford C. Connett sold 4,036 shares of the business’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total value of $287,161.40. Following the sale, the chief executive officer now owns 62,688 shares of the company’s stock, valued at $4,460,251.20. The trade was a 6.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Philip A. Laskawy sold 2,604 shares of the business’s stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total transaction of $184,988.16. Following the sale, the director now directly owns 24,805 shares in the company, valued at $1,762,147.20. The trade was a 9.50 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

Institutional Trading of Henry Schein

Hedge funds and other institutional investors have recently made changes to their positions in the stock. CIBC Asset Management Inc lifted its holdings in shares of Henry Schein by 7.0% in the third quarter. CIBC Asset Management Inc now owns 17,680 shares of the company’s stock worth $1,289,000 after buying an additional 1,162 shares in the last quarter. Natixis Advisors LLC increased its stake in Henry Schein by 18.8% in the 3rd quarter. Natixis Advisors LLC now owns 81,877 shares of the company’s stock worth $5,969,000 after acquiring an additional 12,930 shares during the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Henry Schein by 1,848.9% during the 3rd quarter. Thrivent Financial for Lutherans now owns 105,415 shares of the company’s stock valued at $7,685,000 after acquiring an additional 100,006 shares during the last quarter. Pathstone Holdings LLC increased its position in shares of Henry Schein by 3.1% in the third quarter. Pathstone Holdings LLC now owns 24,028 shares of the company’s stock worth $1,752,000 after purchasing an additional 732 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Henry Schein in the third quarter valued at approximately $515,000. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.